![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
"Immunogenicity of COVID-19 vaccines in patients with cirrhosis: Expected advantage for additional dose of vaccine." Human Vaccines & Immunotherapeutics, 20(1), pp.
This article responds to:
Authors’ contribution
HP 50% ideas, writing, analyzing, approval.
VW 50% ideas, supervision, approval.
Additional information
Funding
The author(s) reported there is no funding associated with the work featured in this article.